CN109568564B - Polypeptide component compound, polypeptide component double-layer tablet, preparation process and application - Google Patents
Polypeptide component compound, polypeptide component double-layer tablet, preparation process and application Download PDFInfo
- Publication number
- CN109568564B CN109568564B CN201811636651.4A CN201811636651A CN109568564B CN 109568564 B CN109568564 B CN 109568564B CN 201811636651 A CN201811636651 A CN 201811636651A CN 109568564 B CN109568564 B CN 109568564B
- Authority
- CN
- China
- Prior art keywords
- parts
- polypeptide
- polypeptide component
- raw material
- layer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/06—Tripeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/285—Aucklandia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/82—Theaceae (Tea family), e.g. camellia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/889—Arecaceae, Palmae or Palmaceae (Palm family), e.g. date or coconut palm or palmetto
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/01—Hydrolysed proteins; Derivatives thereof
- A61K38/012—Hydrolysed proteins; Derivatives thereof from animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
Abstract
A polypeptide component compound, a polypeptide component double-layer tablet, a preparation process and an application relate to the field of polypeptide products. The polypeptide component compound comprises the following raw materials in parts by weight: 7-70 parts of a polypeptide component; 1-5 parts of a golden camellia extract; 1-5 parts of assai extractive; and saussurea involucrate culture 1-5 parts. The polypeptide component compound provided by the embodiment of the invention is used for preparing an oral preparation product for enhancing immunity. The polypeptide assembly double-layer sheet comprises a first sheet layer and a second sheet layer which are overlapped together, wherein the first sheet layer comprises a polypeptide component, and the second sheet layer comprises a golden camellia extract, an assai fruit extract and a saussurea involucrate culture. The polypeptide component compound, the polypeptide component double-layer tablet, the preparation process and the application of the polypeptide component compound and the polypeptide component double-layer tablet are prepared by matching the polypeptide and the herbaceous plants, provide protein nutrition for organisms, have the efficacy of herbaceous plants, have the efficacy of improving the immunity of the organisms, are convenient to take and have good absorptivity.
Description
Technical Field
The invention relates to the field of polypeptide products, and in particular relates to a polypeptide component compound, a polypeptide component double-layer tablet, a preparation process and application.
Background
Immunity is the body's own defense mechanism, and is the body's ability to recognize and destroy any foreign body such as viruses, bacteria, etc. invaded from the outside, to treat aged, damaged, dead, denatured self cells, and to recognize and treat mutant cells and virus-infected cells in the body. Modern immunology considers that immunity is the physiological response of the human body to recognize and eliminate "isohexia". The immune system performs this function in the human body. Therefore, the immunity is low, viral diseases are easy to invade, the cold is easy to happen, the diseases are difficult to be cured radically, and the treatment course of the diseases after the diseases are suffered is long. The immunity of the human body is enhanced, the occurrence of viral diseases can be prevented, the generation and the development of bacterial diseases can be controlled and reduced, the quality of the human body can be improved, and the cure of most diseases can be accelerated.
There are many methods for enhancing autoimmunity, wherein the traditional Chinese medicine for enhancing immunity has no toxicity and no side effect, for example, the rare traditional Chinese medicines such as cordyceps sinensis, gastrodia elata and the like enhance the immunity of human bodies, but the cost is high, so that the traditional Chinese medicine is difficult to accept by the general public.
Disclosure of Invention
In order to solve at least one technical problem in the prior art, the embodiment of the invention provides a polypeptide component compound, a polypeptide component double-layer tablet, a preparation process and an application thereof.
The technical problem to be solved by the invention is realized by adopting the following technical scheme.
In a first aspect, a polypeptide module compound is provided, which comprises the following raw materials in parts by weight:
in the technical scheme, the polypeptide in the polypeptide component is a compound formed by connecting alpha-amino acids together by peptide bonds, and is also an intermediate product of proteolysis, and the polypeptide has the effects of immunoregulation, antibiosis, tumor resistance and the like and has good absorption performance. The golden camellia extract is extracted from golden camellia, and the golden camellia is rich in various natural nutritional ingredients such as tea polysaccharide, tea polyphenol, total saponin, total flavone, tea pigment, caffeine, protein, vitamin, folic acid, fatty acid and the like, also contains dozens of amino acids such as theanine, threonine and the like, is rich in various natural organic trace elements and macro elements which have important health care effects on human bodies, and has the effects of enhancing immunity, reducing blood sugar and urine sugar; the assai extractive is extracted from the assai fruits, and a large amount of antioxidant and other minerals contained in the assai fruits can provide basic nutrients and resist free radicals, so the assai fruits have extremely strong vitality and health care effects; the saussurea involucrate culture not only contains active ingredients similar to natural saussurea involucrate, but also has pharmacological activities in various aspects equivalent to the active ingredients, has main pharmacological effects of analgesia, anti-inflammation, antirheumatic, platelet aggregation inhibition, blood fat reduction, blood circulation improvement, immune system regulation, and also has pharmacodynamic effects in various aspects such as oxidation resistance, radiation resistance, fatigue resistance and the like.
The polypeptide component compound of the embodiment is formed by the compatibility of a polypeptide component and three natural herbal plant products of a golden camellia extract, an assai extractive and a snow lotus culture. The three natural herbal plant products of the golden camellia extract, the assai extractive and the saussurea involucrate culture have the effects of enhancing immunity and the like, are non-toxic and free of side effect, and have low cost relative to rare traditional Chinese medicinal materials. The three natural herbal plant products are matched with the polypeptide components with the same effects of enhancing immunity and the like, have rich protein nutrition and the functional components of the natural herbal plants, provide protein nutrition for organisms and the effects of the herbal plants, have the effect of improving the immunity of the organisms, are convenient to take and have good absorptivity.
In one possible implementation mode, the raw materials comprise the following components in parts by weight:
in the technical scheme, the polypeptide component has stronger compatibility and synergistic effect with three natural herbal plant products, namely, the golden camellia extract, the assai extractive and the saussurea involucrate culture, and particularly has more remarkable effect of enhancing the immunity.
In one possible implementation manner, the polypeptide component includes, in parts by weight:
1-25 parts of collagen tripeptide;
5-25 parts of albumin polypeptide; and
1-20 parts of oyster peptide.
In the technical scheme, the collagen tripeptide is the minimum structural unit of collagen prepared by taking pig skin and fish skin as raw materials by utilizing an advanced bioengineering technology, is a tripeptide containing glycine, proline (or hydroxyproline) and one other amino acid, has small molecular weight and can be fully absorbed by a human body; albumin polypeptide, namely albumin polypeptide, ovalbumin polypeptide or chicken ovalbumin polypeptide, has the functions of regulating nutrition and regulating immunity; the oyster peptide is a micromolecular oligopeptide, completely retains the original nutrients of the oysters such as vitamins, trace elements, taurine and the like, ensures that the oysters rich in nucleic acid can be absorbed more quickly than single amino acid or protein after being ingested by a human body, and has the effects of enhancing the immunity and protecting the liver. The collagen tripeptide, the albumin polypeptide and the oyster peptide are combined to form a polypeptide component, the amino acid content is rich, rich protein nutrition is provided for organisms, and meanwhile, the polypeptide components adopted in the embodiment are all micromolecular polypeptides, so that the collagen tripeptide, the albumin polypeptide and the oyster peptide have excellent absorption performance and can not increase the gastrointestinal burden of the organisms; moreover, the polypeptide component has good synergistic effect with the three natural herbal plant products of the embodiment, and has stronger function of enhancing immunity.
In one possible implementation manner, the polypeptide component includes, in parts by weight:
5-15 parts of collagen tripeptide;
5-15 parts of albumin polypeptide; and
5-15 parts of oyster peptide.
In the technical scheme, the compatibility and the synergistic effect of the collagen tripeptide, the albumin polypeptide and the oyster peptide are stronger, and particularly, the effect of enhancing the immunity is more obvious.
In a possible implementation manner, the raw material further comprises 5-25 parts by weight of nucleotide, and optionally, the raw material further comprises 5-10 parts by weight of nucleotide.
In the technical scheme, the nucleotide is a compound consisting of purine base or pyrimidine base, ribose or deoxyribose and phosphate, and is added into the polypeptide component compound, so that the immunity can be regulated, and the immunity can be further enhanced.
In a second aspect, a preparation process of the polypeptide component compound is provided, wherein raw materials are prepared into an oral preparation product according to the preparation process of the oral preparation.
In the technical scheme, the preparation process of the oral preparation is mature and easy to popularize, the prepared oral preparation product is wide in audience, and the effective components are easy to absorb.
In a third aspect, there is provided a use of the polypeptide module complex as described above for preparing an oral formulation product for enhancing immunity.
In the technical scheme, the polypeptide component compound has the function of enhancing immunity, and accordingly, the polypeptide component compound can be prepared into products for enhancing immunity, especially oral preparation products, and is wide in audience range and easy to absorb effective components.
According to a fourth aspect, a polypeptide assembly double-layer sheet is provided, which comprises a first sheet layer and a second sheet layer which are stacked together, wherein the first raw material of the first sheet layer comprises 7-70 parts by weight of polypeptide components, and the second raw material of the second sheet layer comprises:
1-5 parts of a golden camellia extract;
1-5 parts of assai extractive; and
1-5 parts of saussurea involucrata culture.
In the technical scheme, the first sheet layer and the second sheet layer are combined into a whole, the taking mode is convenient, the carrying is convenient, the first raw material and the second raw material cannot be mixed before the polypeptide component double-layer tablet product is taken, for example, in the storage process, only the first raw material and the second raw material of the contact surface are contacted, namely, the polypeptide component and the natural herbal plant product cannot be mixed and cannot interact with each other, so that the polypeptide component double-layer tablet has long storage time, is not easy to lose efficacy and has the effect of enhancing the immunity.
In a fifth aspect, a preparation process of the polypeptide module bilayer tablet is provided, which comprises a step of performing bilayer tablet pressing on the first raw material and the second raw material.
In the technical scheme, the double-layer tablet can compound the polypeptide component and the natural herbal plant product together, is convenient to take, cannot influence each other, and avoids failure.
In one possible implementation, it comprises the following steps:
the first raw material and the second raw material are subjected to wet granulation, drying and sieving respectively, and then the sieved first raw material and second raw material are subjected to double-layer tabletting.
In the technical scheme, the first raw material and the second raw material are subjected to wet granulation, drying, sieving and tabletting respectively, so that the good dispersibility of the effective components in the first raw material and the second raw material can be ensured.
Drawings
In order to more clearly illustrate the technical solutions of the embodiments of the present invention, the drawings needed to be used in the embodiments will be briefly described below, it should be understood that the following drawings only illustrate some embodiments of the present invention and therefore should not be considered as limiting the scope, and for those skilled in the art, other related drawings can be obtained according to the drawings without inventive efforts.
FIG. 1 is a graph showing the effect of the polypeptide module tablet of example 3 on the mouse organ index;
FIG. 2 is a graph showing the effect of the polypeptide module tablet of example 3 on the ability of mouse macrophages to phagocytose chicken erythrocytes;
FIG. 3 is a graph showing the results of the effect of the polypeptide module tablet of example 3 on the NK cell activity of mice.
Detailed Description
In order to make the objects, technical solutions and advantages of the embodiments of the present invention clearer, the technical solutions in the embodiments of the present invention will be clearly and completely described below. The examples, in which specific conditions are not specified, were conducted under conventional conditions or conditions recommended by the manufacturer. The reagents or instruments used are not indicated by the manufacturer, and are all conventional products available commercially.
The polypeptide module complex, the polypeptide module double-layer tablet, and the preparation process and application of the embodiments of the present invention are specifically described below.
The invention provides a polypeptide component compound which comprises the following raw materials in parts by weight: 7-70 parts of a polypeptide component; 1-5 parts of a golden camellia extract; 1-5 parts of assai extractive; and saussurea involucrate culture 1-5 parts. Optionally, the raw materials include, by weight: 15-45 parts of polypeptide component; 3-5 parts of a golden camellia extract; 3-5 parts of an assai extractive; and 3-5 parts of saussurea involucrata culture.
The polypeptide components and the saussurea involucrate culture can be purchased from commercial products or prepared by self; the Camellia nitidissima extract can be purchased commercially, or can be extracted by itself, such as powder obtained by extracting Camellia nitidissima by conventional extraction process, and the Assaya extract can be purchased commercially, or can be extracted by itself, such as powder obtained by extracting Assaya by conventional extraction process. As an example, the extraction process of the camellia nitidissima extract is as follows:
mixing Camellia Chysantha with 10-15 times of water by mass, boiling for 3-5 hr, filtering with plate frame, collecting filtrate A, adding 5-10 times of water into the residue, boiling for 1-3 hr, filtering with plate frame, collecting filtrate B, mixing filtrate A and filtrate B, and spray drying to obtain Camellia Chysantha extract.
The specific components of the polypeptide component are not particularly limited in this example, and may be any one polypeptide or a mixture of at least two polypeptides. Optionally, as an example, the polypeptide component comprises, in parts by weight: 1-25 parts of collagen tripeptide; 5-25 parts of albumin polypeptide; and 1-20 parts of oyster peptide. Optionally, the polypeptide components comprise, by weight: 5-15 parts of collagen tripeptide; 5-15 parts of albumin polypeptide; and 5-15 parts of oyster peptide.
Optionally, as an example, the raw material further includes 5 to 25 parts by weight of nucleotide, and optionally, the raw material further includes 5 to 10 parts by weight of nucleotide.
Optionally, as an example, the polypeptide component compound is made into a tablet, and the raw material further includes an auxiliary material, and the auxiliary material is at least one selected from a diluent, a disintegrating agent, a lubricant and a binder. The diluent is at least one selected from calcium hydrogen phosphate, microcrystalline cellulose, anhydrous lactose, hydrated lactose, calcium phosphate, dicalcium phosphate, tricalcium phosphate, mannitol, sorbitol, sucrose, inositol, trehalose, xylitol, corn starch, kaolin, and bentonite; the lubricant is selected from at least one of magnesium stearate, sodium stearyl fumarate, calcium stearate, zinc stearate, stearic acid, polyethylene glycol with molecular weight not less than 6000, pulvis Talci, sodium benzoate, poloxamer, silicon dioxide, corn starch, pulvis Talci, and magnesium trisilicate. The addition amount of the raw materials is determined according to the quality requirements (forming and disintegration) of the tablets.
The embodiment of the invention provides a preparation process of the polypeptide component compound, which is used for preparing an oral preparation product from raw materials according to the preparation process of the oral preparation.
The present embodiment does not limit the type of the oral preparation product, and the oral preparation product may be a liquid preparation or a solid preparation, such as oral preparations such as powder, tablet, granule, capsule, etc.; correspondingly, the preparation process of the polypeptide component compound is adjusted according to the dosage form of the product.
The embodiment of the invention provides application of the polypeptide component compound, and the polypeptide component compound is used for preparing an oral preparation product for enhancing immunity.
The embodiment of the invention provides a polypeptide assembly double-layer sheet, which comprises a first sheet layer and a second sheet layer which are overlapped together, wherein the first raw material of the first sheet layer comprises 7-70 parts of polypeptide components according to parts by weight, and the second raw material of the second sheet layer comprises: 1-5 parts of a golden camellia extract; 1-5 parts of assai extractive; and saussurea involucrate culture 1-5 parts.
Optionally, as an example, the first raw material and/or the second raw material further includes 5 to 25 parts by weight of nucleotide. Specifically, the nucleotide may be added to only the first raw material, the nucleotide may be added to only the second raw material, or the nucleotide may be added to both the first raw material and the second raw material.
Optionally, as an example, the first raw material and/or the second raw material further includes an auxiliary material, and the auxiliary material is at least one selected from a diluent, a disintegrating agent, a lubricant, and a binder. The diluent is at least one selected from calcium hydrogen phosphate, microcrystalline cellulose, anhydrous lactose, hydrated lactose, calcium phosphate, dicalcium phosphate, tricalcium phosphate, mannitol, sorbitol, sucrose, inositol, trehalose, xylitol, corn starch, kaolin, and bentonite; the lubricant is selected from at least one of magnesium stearate, sodium stearyl fumarate, calcium stearate, zinc stearate, stearic acid, polyethylene glycol with molecular weight not less than 6000, pulvis Talci, sodium benzoate, poloxamer, silicon dioxide, corn starch, pulvis Talci, and magnesium trisilicate.
In this embodiment, the pharmaceutically acceptable auxiliary materials may be added to only the first raw material, only the second raw material, or both the first raw material and the second raw material. Optionally, in order to enable the first raw material to be tableted to form a first sheet layer and enable the second raw material to be tableted to form a second sheet layer, pharmaceutically acceptable common auxiliary materials for tablets are added into the first raw material and the second raw material, and the adding amount of the auxiliary materials in the first sheet layer and the second sheet layer is determined according to the quality requirement of the tablets.
The embodiment of the invention provides a preparation process of the polypeptide assembly double-layer tablet, which comprises the step of carrying out double-layer tabletting on a first raw material and a second raw material. Optionally, as an example, the polypeptide assembly double-layer tablet is formed by compressing through a double-layer tablet press, in the compression process, the first raw material is firstly compressed to form a first tablet layer, and the second raw material is secondly compressed to form a second tablet layer, so that when the polypeptide assembly double-layer tablet is in the stamping die, the first tablet layer is in the lower layer, and the second tablet layer is in the upper layer.
Optionally, as an example, it includes the following steps:
the first raw material and the second raw material are subjected to wet granulation, drying and sieving respectively, and then the sieved first raw material and second raw material are subjected to double-layer tabletting.
The features and properties of the present invention are described in further detail below with reference to examples.
It should be noted that the collagen tripeptide, albumin polypeptide and oyster peptide of the following examples are all products produced and sold by Wuhan Tiantianhao biological products Limited; purchasing nucleotide from the product produced and sold in Dalian Lianzhen ao; the Ishikao extract is purchased from a product produced and sold by Beijing Zhongkang; the saussurea involucrate culture is purchased from products produced and sold by the Dalian Puruikang; the golden camellia extract is self-extracted, and the specific extraction process comprises the following steps:
mixing the golden camellia with 15 mass times of water, boiling for 4 hours, filtering by using a plate frame, reserving filtrate A, adding 10 mass times of water into filter residues, boiling for 2 hours, filtering by using the plate frame, reserving filtrate B, fully mixing the filtrate A and the filtrate B, and performing spray drying to obtain the golden camellia extract.
Example 1
The present example provides a polypeptide module tablet, which is prepared according to the following preparation method:
preparing materials: collagen tripeptide 1 part, albumin polypeptide 5 parts, oyster peptide 1 part, golden camellia extract 5 parts, assai fruit extract 5 parts, saussurea involucrate culture 1 part, sorbitol 5 parts, microcrystalline cellulose 15 parts, silicon dioxide 0.5 part and magnesium stearate 5 parts.
Placing collagen tripeptide, albumin polypeptide, oyster peptide, golden camellia extract, assai extractive, saussurea involucrate culture, sorbitol, microcrystalline cellulose and a proper amount of lactose into a wet granulator, uniformly mixing, adding 95% ethanol with the feeding amount of about 20%, stirring for about 2min, discharging, drying until the water content is about 3%, drying at the temperature of not more than 60 ℃, and sieving with a 20-30 mesh sieve after drying; placing the sieved materials, silicon dioxide and magnesium stearate in a three-dimensional mixer for 30 min; and tabletting the mixed material by adopting a tabletting machine.
Example 2
This example provides a polypeptide module tablet prepared substantially the same as example 1 except that:
preparing materials in this embodiment: 25 parts of collagen tripeptide, 25 parts of albumin polypeptide, 1 part of oyster peptide, 5 parts of golden camellia extract, 5 parts of assai fruit extract, 5 parts of saussurea involucrate culture, 20 parts of sorbitol, 40 parts of microcrystalline cellulose, 10 parts of silicon dioxide and 20 parts of magnesium stearate.
Example 3
This example provides a polypeptide module tablet prepared substantially the same as example 1 except that:
preparing materials in this embodiment: 10 parts of collagen tripeptide, 10 parts of albumin polypeptide, 10 parts of oyster peptide, 3.75 parts of golden camellia extract, 3.75 parts of assai fruit extract, 3.75 parts of saussurea involucrate culture, 5 parts of nucleotide, 10 parts of sorbitol, 28 parts of microcrystalline cellulose, 6 parts of silicon dioxide and 6 parts of magnesium stearate.
Example 4
This example provides a polypeptide module tablet prepared substantially the same as example 1 except that:
preparing materials in this embodiment: 5 parts of collagen tripeptide, 5 parts of albumin polypeptide, 5 parts of oyster peptide, 5 parts of golden camellia extract, 5 parts of assai fruit extract, 5 parts of snow lotus culture, 5 parts of nucleotide, 20 parts of sorbitol, 40 parts of microcrystalline cellulose, 10 parts of silicon dioxide and 20 parts of magnesium stearate.
Example 5
This example provides a polypeptide module tablet prepared substantially the same as example 1 except that:
preparing materials in this embodiment: 15 parts of collagen tripeptide, 15 parts of albumin polypeptide, 15 parts of oyster peptide, 5 parts of golden camellia extract, 5 parts of assai fruit extract, 5 parts of snow lotus culture, 5 parts of nucleotide, 10 parts of sorbitol, 30 parts of microcrystalline cellulose, 5 parts of silicon dioxide and 10 parts of magnesium stearate.
Example 6
The present example provides a polypeptide module bilayer tablet, which is prepared according to the following preparation method:
preparing materials: 10 parts of collagen tripeptide, 10 parts of albumin polypeptide, 10 parts of oyster peptide, 3.75 parts of golden camellia extract, 3.75 parts of assai fruit extract, 3.75 parts of saussurea involucrate culture, 5 parts of nucleotide, 10 parts of sorbitol, 28 parts of microcrystalline cellulose, 6 parts of silicon dioxide and 6 parts of magnesium stearate.
Preparing a first raw material: putting collagen tripeptide, albumin polypeptide, oyster peptide, a proper amount of lactose, 1/4 total sorbitol and 1/4 total microcrystalline cellulose into a wet granulator, uniformly mixing, adding 95% ethanol with the addition amount of about 20%, stirring for about 2min, discharging, drying until the water content is about 3%, drying at the temperature of not more than 60 ℃, sieving by a 20-30 mesh sieve, putting the sieved material, 1/4 total silicon dioxide and 1/4 total magnesium stearate into a three-dimensional mixer for 30min, and tabletting.
Preparing a second raw material: placing the camellia sinensis extract, the assai fruit, the saussurea involucrate culture, the nucleotide, the lactose, the rest sorbitol and the rest microcrystalline cellulose in a wet granulator, uniformly mixing, adding 95% ethanol with the feeding amount of about 20%, stirring for about 2min, discharging, drying until the water content is about 3%, the drying temperature is not more than 60 ℃, sieving with a 20-30 mesh sieve after drying, placing the sieved material, the rest silicon dioxide and the rest magnesium stearate in a three-dimensional mixer for 30min, and tabletting.
And carrying out double-layer tabletting treatment on the first raw material and the second raw material by adopting a double-layer tabletting process.
Example 7
The present example provides a polypeptide module bilayer tablet, which is prepared according to the following preparation method:
preparing materials: 5 parts of collagen tripeptide, 5 parts of albumin polypeptide, 5 parts of oyster peptide, 5 parts of golden camellia extract, 5 parts of assai fruit extract, 5 parts of snow lotus culture, 5 parts of nucleotide, 20 parts of sorbitol, 40 parts of microcrystalline cellulose, 10 parts of silicon dioxide and 20 parts of magnesium stearate.
Preparing a first raw material: placing collagen tripeptide, albumin polypeptide, oyster peptide, lactose, total amount of sorbitol 1/2 and total amount of microcrystalline cellulose 1/2 in a wet granulator, uniformly mixing, adding 95% ethanol with a feeding amount of about 20%, stirring for about 2min, discharging, drying until the water content is about 3%, drying at a temperature of no more than 60 ℃, sieving with a 20-30 mesh sieve, placing the sieved material, total amount of silicon dioxide 1/2 and total amount of magnesium stearate 1/2 in a three-dimensional mixer for 30min, and tabletting
Preparing a second raw material: placing the camellia sinensis extract, the assai fruit, the saussurea involucrate culture, the nucleotide, the lactose, the rest sorbitol and the rest microcrystalline cellulose in a wet granulator, uniformly mixing, adding 95% ethanol with the feeding amount of about 20%, stirring for about 2min, discharging, drying until the water content is about 3%, the drying temperature is not more than 60 ℃, sieving with a 20-30 mesh sieve after drying, placing the sieved material, the rest silicon dioxide and the rest magnesium stearate in a three-dimensional mixer for 30min, and tabletting.
And carrying out double-layer tabletting treatment on the first raw material and the second raw material by adopting a double-layer tabletting process.
The effect of the product of the embodiment of the invention on enhancing immunity is verified by animal experiments.
Firstly, experimental animals: feeding Kunming mice 20 + -2 g, 100 mice, 20-25 deg.C, humidity 50% -65%, adaptively feeding with common feed for 3 days, dividing into 5 groups, which are respectively normal control group, albumin polypeptide group, low dose group, middle dose group, and high dose group, and feeding normal control group with stomach distilled water; the single albumin polypeptide is perfused into the stomach by albumin polypeptide group, and the dose of each perfusion is 1.0 g/kg; the polypeptide component tablets in the example 3 are infused in a low dose group, a medium dose group and a high dose group, wherein the doses of the infusion are respectively 0.5g/kg, 1.0g/kg and 2.0g/kg, and the administration is continuously carried out for 30 days.
1. Organ/body weight ratio measurement: spleen and thymus were weighed and the visceral/somatic ratio was calculated, and fig. 1 is a graph showing the effect of different products on the visceral index of mice.
2. Experiment of phagocytosis of chicken red blood cells by macrophages in abdominal cavity of mouse: injecting 1ml of 20% chicken erythrocyte suspension into the abdominal cavity, killing a mouse by cervical dislocation after 30min, injecting 2ml of normal saline into the abdominal cavity, fully mixing, sucking 1ml of abdominal cavity cleaning solution, taking 2 drops of the cleaning solution, placing the cleaning solution on a glass slide, incubating for 30min at 37 ℃, rinsing with the normal saline, drying, fixing, dyeing and counting, wherein fig. 2 is a graph showing the influence of different products on the chicken erythrocyte phagocytosis capacity of mouse macrophages.
3. Determination of NK cell Activity: YAC-1 cells (target cells) were subcultured 24h before the experiment, and the cell concentration was adjusted to 4X 10 with RPMI1640 complete medium5Taking spleen aseptically to prepare single cell suspension, washing with Hank's solution for 3 times, adjusting cell concentration to 2 × 107Taking 100ul of target cells and effector cells, adding into 96-well plate, adding into natural release hole of target cells100ul of target cells and culture solution respectively, 100ul of target cells and 100ul of 1% NP40 are added into the maximum release holes of the target cells, each hole is repeated for 3 times, the target cells and the NP are cultured for 4 hours at 37 ℃ in a 5% carbon dioxide incubator, 100ul of supernatant is sucked and placed in a flat-bottom 96-well plate, 100ul of LDH base solution is added, the reaction is carried out for 3min, 1mol/l HCL130ul is added, the measurement is carried out at 492nm, and a graph 3 shows the influence of different products on the NK cell activity of mice.
The experimental results show that the product of example 3 has significant or very significant differences in the phagocytosis of chicken erythrocytes and NK cell activity by macrophages, and has more obvious effects compared with albumin polypeptide alone. In addition, the results of the tests on the products of examples 1-2 and 4-7 were confirmed by the same animal experiments as described above, and it was found that the products of examples 1-2 and 4-7 have significant or very significant differences in spleen and thymus index, ability of macrophages to phagocytose chicken erythrocytes, and NK cell activity of mice, and thus the products of the present invention have a strong immunopotentiation effect on the experimental mice.
In summary, the polypeptide component compound, the polypeptide component double-layer tablet, the preparation process and the application of the polypeptide component compound and the polypeptide component double-layer tablet provided by the embodiment of the invention are prepared by compatibility of the polypeptide and the herbaceous plant, provide protein nutrition for an organism, have the efficacy of herbaceous plants, have the efficacy of improving the immunity of the organism, are convenient to take, and have good absorptivity.
The embodiments described above are some, but not all embodiments of the invention. The detailed description of the embodiments of the present invention is not intended to limit the scope of the invention as claimed, but is merely representative of selected embodiments of the invention. All other embodiments, which can be derived by a person skilled in the art from the embodiments given herein without making any creative effort, shall fall within the protection scope of the present invention.
Claims (7)
1. The polypeptide assembly double-layer sheet is characterized by comprising a first sheet layer and a second sheet layer which are stacked together, wherein the first raw material of the first sheet layer comprises 7-70 parts by weight of a polypeptide component, and the second raw material of the second sheet layer comprises:
1-5 parts of a golden camellia extract;
1-5 parts of assai extractive; and
1-5 parts of saussurea involucrate culture;
the polypeptide component comprises the following components in parts by weight:
1-25 parts of collagen tripeptide;
5-25 parts of albumin polypeptide; and
1-20 parts of oyster peptide.
2. The polypeptide module bilayer tablet of claim 1 wherein the first starting material comprises 15-45 parts by weight of the polypeptide module and the second starting material comprises:
3-5 parts of the golden camellia extract;
3-5 parts of the assai extractive; and
3-5 parts of saussurea involucrate culture.
3. The polypeptide module bilayer tablet of claim 1 wherein the polypeptide component comprises, in parts by weight:
5-15 parts of collagen tripeptide;
5-15 parts of albumin polypeptide; and
5-15 parts of oyster peptide.
4. The polypeptide module bilayer tablet of claim 1 wherein the second starting material further comprises 5-25 parts by weight of nucleotides.
5. The polypeptide module bilayer tablet of claim 4 wherein the second starting material further comprises 5-10 parts by weight of nucleotides.
6. A process for the preparation of a bi-layer tablet of a polypeptide module according to claim 1, comprising the step of bi-layer tabletting said first material and said second material.
7. Process for the preparation of a polypeptide module bilayer tablet according to claim 6 comprising the steps of:
the first raw material and the second raw material are subjected to wet granulation, drying and sieving respectively, and then the sieved first raw material and the sieved second raw material are subjected to double-layer tabletting.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811636651.4A CN109568564B (en) | 2018-12-29 | 2018-12-29 | Polypeptide component compound, polypeptide component double-layer tablet, preparation process and application |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811636651.4A CN109568564B (en) | 2018-12-29 | 2018-12-29 | Polypeptide component compound, polypeptide component double-layer tablet, preparation process and application |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN109568564A CN109568564A (en) | 2019-04-05 |
| CN109568564B true CN109568564B (en) | 2022-04-29 |
Family
ID=65933564
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201811636651.4A Active CN109568564B (en) | 2018-12-29 | 2018-12-29 | Polypeptide component compound, polypeptide component double-layer tablet, preparation process and application |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN109568564B (en) |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1202821A (en) * | 1995-10-23 | 1998-12-23 | 瑟垃技术有限公司 | Compositions and methods for buccal delivery of pharmaceutical agent |
| WO2005037203A2 (en) * | 2003-10-15 | 2005-04-28 | Combinatorx, Incorporated | Methods and reagents for the treatment of immunoinflammatory disorders |
| CN104824660A (en) * | 2015-04-08 | 2015-08-12 | 王书敏 | Collagen-saussurea involucrata small peptide effervescent tablet and preparation method thereof |
| EP2944313A1 (en) * | 2006-01-19 | 2015-11-18 | Mary Kay, Inc. | Compositions comprising kakadu plum extract or acai berry extract |
| CN108618128A (en) * | 2018-05-08 | 2018-10-09 | 广州莱可福生物科技有限公司 | Adjust the composition and its preparation method and application of immunity |
-
2018
- 2018-12-29 CN CN201811636651.4A patent/CN109568564B/en active Active
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1202821A (en) * | 1995-10-23 | 1998-12-23 | 瑟垃技术有限公司 | Compositions and methods for buccal delivery of pharmaceutical agent |
| WO2005037203A2 (en) * | 2003-10-15 | 2005-04-28 | Combinatorx, Incorporated | Methods and reagents for the treatment of immunoinflammatory disorders |
| EP2944313A1 (en) * | 2006-01-19 | 2015-11-18 | Mary Kay, Inc. | Compositions comprising kakadu plum extract or acai berry extract |
| CN104824660A (en) * | 2015-04-08 | 2015-08-12 | 王书敏 | Collagen-saussurea involucrata small peptide effervescent tablet and preparation method thereof |
| CN108618128A (en) * | 2018-05-08 | 2018-10-09 | 广州莱可福生物科技有限公司 | Adjust the composition and its preparation method and application of immunity |
Non-Patent Citations (2)
| Title |
|---|
| "Effects of combined extract of cocoa, coffee,green tea and garcinia on lipid profiles, glycaemic markers and inflammatory responses in hamsters";Chih-Wei Chang et al.;《BMC》;20151231;第15卷;第1-11页 * |
| "雪莲花水提物的抗氧化活性及其机制";张振明等;《第二军医大学学报》;20050531;第26卷(第5期);第568-570页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN109568564A (en) | 2019-04-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5946457B2 (en) | Application of herbal medicine composition to the preparation of health foods and medicines for the relief and prevention treatment of physical fatigue | |
| CN102100805B (en) | Composition for relieving physical fatigue and enhancing immunologic function, preparation method thereof and application thereof | |
| CN111557449A (en) | Composition with function of improving immunity and preparation method thereof | |
| CN104740412B (en) | A kind of Medicament for Alcoholism composition and preparation method thereof | |
| CN106420886A (en) | Composition with physical fatigue alleviating and immunity enhancing functions, and preparation method thereof | |
| CN101716256B (en) | Preparation used for strengthening immunity | |
| CN102600212A (en) | Medicinal health product for immunity enhancement and adjuvant treatment of tumor | |
| CN103564495A (en) | Propolis and cordycepic hypha powder composition, as well as preparation and application thereof | |
| CN103142916B (en) | Medicament for preventing and treating senile dementia and preparation method thereof | |
| CN109568564B (en) | Polypeptide component compound, polypeptide component double-layer tablet, preparation process and application | |
| CN101647816A (en) | Bionic enzymatic hydrolysate for animal skins and application thereof | |
| KR101731859B1 (en) | A composition for the prevention or treatment of abnormal weight loss comprising Citrus Unshiu Peel extract | |
| KR20090071704A (en) | Composition for prevention and treatment of the dementia | |
| CN108420890B (en) | Composition with blood fat reducing effect and preparation method thereof | |
| CN108066384A (en) | A kind of Chinese medicine preparation with strengthen immunity and preparation method thereof | |
| CN110772564A (en) | Traditional Chinese medicine extract composition with depression mood regulating effect, preparation method thereof and traditional Chinese medicine preparation | |
| CN102132873A (en) | Medicine or health-care food for supplementing blood and regulating immunity | |
| CN105832877B (en) | A kind of health care product and its preparation method and application with liver-protecting efficacy | |
| CN111184758B (en) | Composition containing caulis Mahoniae alcohol extract and cordycepin, preparation and application thereof | |
| CN102078600B (en) | Anti-cancer compound ganoderma composition, application thereof and pharmaceutical composition containing same | |
| CN104353057B (en) | Blood-pressure reducing health care product containing european bird cherry anthocyanogen | |
| RU2332866C2 (en) | Dietary supplement "perstevit" | |
| CN106214844A (en) | A kind of compositions with fat-reducing and immunoregulation effect and preparation method thereof | |
| CN106214887A (en) | A kind of can antitumor, improve immunity pharmaceutical composition | |
| CN111838666A (en) | Composition with auxiliary memory improving function and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |